Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. more
Time Frame | CMPX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -14.97% | -2.06% | -0.55% |
1-Month Return | 5.19% | -1.92% | 2.72% |
3-Month Return | -12.88% | -10.4% | 7.66% |
6-Month Return | 26.79% | -4.6% | 10.15% |
1-Year Return | -10.13% | 4.06% | 27.53% |
3-Year Return | -53.9% | 1.94% | 32.31% |
5-Year Return | -83.29% | 36.48% | 89.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 2.12M | 2.40M | 1.62M | 1.90M | 1.89M | [{"date":"2019-12-31","value":88.19,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":67.55,"profit":true},{"date":"2022-12-31","value":79.2,"profit":true},{"date":"2023-12-31","value":78.62,"profit":true}] |
Gross Profit | (2.12M) | (2.40M) | (1.62M) | (1.90M) | (1.89M) | [{"date":"2019-12-31","value":-212000000,"profit":false},{"date":"2020-12-31","value":-240400000,"profit":false},{"date":"2021-12-31","value":-162400000,"profit":false},{"date":"2022-12-31","value":-190400000,"profit":false},{"date":"2023-12-31","value":-189000000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 34.05M | 27.81M | 31.26M | 41.66M | 48.47M | [{"date":"2019-12-31","value":70.25,"profit":true},{"date":"2020-12-31","value":57.38,"profit":true},{"date":"2021-12-31","value":64.5,"profit":true},{"date":"2022-12-31","value":85.93,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (34.05M) | (27.81M) | (81.88M) | (41.66M) | (50.36M) | [{"date":"2019-12-31","value":-3405200000,"profit":false},{"date":"2020-12-31","value":-2781200000,"profit":false},{"date":"2021-12-31","value":-8188200000,"profit":false},{"date":"2022-12-31","value":-4165500000,"profit":false},{"date":"2023-12-31","value":-5036300000,"profit":false}] |
Total Non-Operating Income/Expense | (1.09M) | (2.48M) | (640.00K) | 4.79M | 15.74M | [{"date":"2019-12-31","value":-6.9,"profit":false},{"date":"2020-12-31","value":-15.73,"profit":false},{"date":"2021-12-31","value":-4.07,"profit":false},{"date":"2022-12-31","value":30.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (34.65M) | (29.47M) | (82.18M) | (39.23M) | (42.49M) | [{"date":"2019-12-31","value":-3465300000,"profit":false},{"date":"2020-12-31","value":-2946800000,"profit":false},{"date":"2021-12-31","value":-8218100000,"profit":false},{"date":"2022-12-31","value":-3922500000,"profit":false},{"date":"2023-12-31","value":-4249400000,"profit":false}] |
Income Taxes | 91.00K | 32.00K | 370.00K | (2.43M) | - | [{"date":"2019-12-31","value":24.59,"profit":true},{"date":"2020-12-31","value":8.65,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-656.76,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (34.74M) | (29.50M) | (82.55M) | (36.80M) | - | [{"date":"2019-12-31","value":-3474400000,"profit":false},{"date":"2020-12-31","value":-2950000000,"profit":false},{"date":"2021-12-31","value":-8255100000,"profit":false},{"date":"2022-12-31","value":-3679500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (34.74M) | (29.50M) | (82.18M) | (39.23M) | (42.49M) | [{"date":"2019-12-31","value":-3474400000,"profit":false},{"date":"2020-12-31","value":-2950000000,"profit":false},{"date":"2021-12-31","value":-8218100000,"profit":false},{"date":"2022-12-31","value":-3922500000,"profit":false},{"date":"2023-12-31","value":-4249400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (34.74M) | (29.50M) | (82.55M) | (36.80M) | (42.49M) | [{"date":"2019-12-31","value":-3474400000,"profit":false},{"date":"2020-12-31","value":-2950000000,"profit":false},{"date":"2021-12-31","value":-8255100000,"profit":false},{"date":"2022-12-31","value":-3679500000,"profit":false},{"date":"2023-12-31","value":-4249400000,"profit":false}] |
EPS (Diluted) | (4.45) | (0.93) | (1.52) | (0.37) | (0.34) | [{"date":"2019-12-31","value":-444.74,"profit":false},{"date":"2020-12-31","value":-92.81,"profit":false},{"date":"2021-12-31","value":-152,"profit":false},{"date":"2022-12-31","value":-37,"profit":false},{"date":"2023-12-31","value":-34,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CMPX | |
---|---|
Cash Ratio | 30.54 |
Current Ratio | 31.84 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CMPX | |
---|---|
ROA (LTM) | -21.71% |
ROE (LTM) | -32.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CMPX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.07 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.93 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CMPX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 247.66 |
P/B | 1.52 |
Price/FCF | NM |
EV/R | 96.45 |
EV/Ebitda | NM |
Compass Therapeutics Inc. (CMPX) share price today is $1.42
Yes, Indians can buy shares of Compass Therapeutics Inc. (CMPX) on Vested. To buy Compass Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CMPX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Compass Therapeutics Inc. (CMPX) via the Vested app. You can start investing in Compass Therapeutics Inc. (CMPX) with a minimum investment of $1.
You can invest in shares of Compass Therapeutics Inc. (CMPX) via Vested in three simple steps:
The 52-week high price of Compass Therapeutics Inc. (CMPX) is $2.34. The 52-week low price of Compass Therapeutics Inc. (CMPX) is $0.77.
The price-to-earnings (P/E) ratio of Compass Therapeutics Inc. (CMPX) is
The price-to-book (P/B) ratio of Compass Therapeutics Inc. (CMPX) is 1.52
The dividend yield of Compass Therapeutics Inc. (CMPX) is 0.00%
The market capitalization of Compass Therapeutics Inc. (CMPX) is $210.51M
The stock symbol (or ticker) of Compass Therapeutics Inc. is CMPX